Aim of study: To investigate the inhibitory effect of Coptidis rhizome aqueous extract (CRAE) on vascular endothelial growth factor (VEGF) expression and tumor angiogenesis in hepatocellular carcinoma (HCC). Methods: Quality control of CRAE was determined. Secretion of VEGF protein and expression of its mRNA in MHCC97L and Hep G2 cells were measured with enzyme-linked immunosorbent assay and quantitative real-time polymerase chain reaction. Synthesis of nascent protein was determined by AHA-protein-labeling technologies. The in vivo antiangiogenic effect of CRAE was evaluated with a xenograft model. Results: Absence of organochlorine pesticides in CRAE was found, and phytochemical analysis showed that its components were in proportion of magnoflorine 2.2%, jatrorrhizine 1.68%, palmatine 4.4%, and berberine 13.8%. CRAE exhibited significant inhibition on VEGF secretion from MHCC97L and HepG2 cells at nontoxic doses. The mRNA transcripts of VEGF could not be inhibited by CRAE; however, synthesis of VEGF nascent protein was potently blocked by CRAE. CRAE intervention increased the phosphorylation of eukaryotic elongation factor 2 (eEF2) in HCC cells, which blocked eEF2 activity for proceeding nascent protein synthesis. The activity of eEF2 was restored in CRAE-treated HCC cells in the presence of A484594, leading to the recovery of VEGF expression. Berberine was found to be the major active component in CRAE; however, CRAE is more effective in inhibiting eEF2 activity compared to berberine treatment alone, suggesting the additive effect of other components present. Reduction of tumor size and neovascularization were observed in mice xenograft model. Conclusion: Our study postulates the antiangiogenic effect of CRAE on hepatocellular carcinoma via an eEF2-driven pathway.
Introduction
Liver cancer is the seventh-most common cancer and thirdmost cancer-related mortality for both sexes in the world, causing about 700 000 deaths annually. 1 Hepatocellular carcinoma (HCC) is the most prevalent type of death-leading liver cancer, with only 15% of liver cancer patients having a 5-year survival rate. 2 The major complications of HCC are ineffectiveness of existing drugs against HCC, lack of biomarkers to diagnose the disease in early and recurrence stages, and other underlying liver diseases, such as cirrhosis and liver fibrosis, 3 which all make the treatment difficult. Even in HCC patients suitable for surgical resection, invasiveness and aggressive metastatic spread of HCC cells have rendered tumor recurrence after resection. 4 Evidences have shown that detachment and spread of tumor cells from one location to another require formation of new blood vessels, 5, 6 a process termed angiogenesis. The loose and irregular structure of new blood vessels allows tumor cells to infiltrate in and migrate to distinct organs. Vascular endothelial growth factor (VEGF) is the most studied angiogenic factor that has a dominant role in responding the proliferation of endothelial cells and vascular permeability. 7 Coptidis rhizome (Huang Lian in Chinese) was well reviewed thousands of years ago in Shen Nong's Herbal Classic for its effect in reducing damp heat, fire, and toxicity in the human body. It is also used for treatment of diarrhea, eye inflammation, and female abdominal pain. 8, 9 Accumulating studies reported pharmacologic benefits of C rhizome and its major component berberine on kidney injury improvement, inflammation prevention, cell growth arrest, autophagic cell death, chemoprevention, hepatoprotection, and improvement in insulin resistance. [10] [11] [12] [13] [14] [15] [16] Studies have also demonstrated downregulation of secretory protein and transcriptional level of VEGF by berberine. This was associated with the activation of ERK and suppression of MMP2 that affected VEGF-induced proliferation of endothelial cells. 17, 18 Another study showed the inhibitory effect of berberine on endothelial cell tube formation through degradation of HIF-1α protein, a transcriptional factor expressed during oxygen depletion. 19 In recent years, C rhizome has been reported to actively suppress cancer progression by inducing apoptosis in colorectal, 20 oral, 21 and breast cancer. 22 Our previous study demonstrated antiinvasive effect of C rhizome aqueous extract (CRAE) in HCC cells via deregulation of F-actin and Rho/ROCK signaling pathway. 23 Upregulation of miR23a and miR21 that is associated with tumor suppression has also been reported on CRAE-intervened HCC cells. 24 The hepatoprotective action of CRAE has been also addressed, which suggests its benefit to the liver organs. 25, 26 However, whether C rhizome could suppress tumor angiogenesis of HCC remains unclear. The underlying mechanism also request further elaboration.
In this study, we focused on VEGF to examine the effect of C rhizome on tumor angiogenesis of HCC. We observed the toxicity of CRAE on MHCC97L and Hep G2 cells and reduction on subcutaneous growth of MHCC97L tumor size in animal model. The effect of CRAE in attenuating secretion of VEGF was associated with inhibition of eukaryotic elongation factor 2 (eEF2) and blockade of nascent protein synthesis. We also proposed the additive effect of other compounds other than berberine in CRAE that contribute to the activity. These findings have unraveled the new molecular mechanism of regulating VEGF expression at the posttranscriptional level by C rhizome and berberine on HCC.
Methods

Chemicals and Reagents
Organochlorine pesticides, berberine, palmatine, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich (US). Jatrorrhizine was purchased from NICPBP (China) and magnoflorine from Tauto Biotech (China). Rabbit monoclonal antibodies against GADPH, eEF2, and peEF2 were purchased from Cell Signaling Technologies (US) and α-tubulin from AbCam (UK). Rabbit polyclonal antibody was purchased from Santa Cruz (US).
Sample Preparation
The dried rhizome of Coptis chinensis Franch species (Ranunculaceae) was collected from Sichuan, China. The collected C rhizome crude herb was washed, dried, and cut into small pieces; 100 g of herb was boiled in 1 L of distilled water at 100°C for 1 hour. The crude extracts were filtered and evaporated in vacuo with a rotary evaporator. The dried concentrated crude extract was stored in −20°C freezer.
Phytochemical Analysis
To determine the presence of organochlorine pesticide in CRAE, the sample was subjected to gas chromatography analysis. Determination was performed on Agilent 6890 N gas chromatography system equipped with 5973 Network mass selective detectors and HP-5MS column (30 m × 0.25 mm × 0.25 µm; Agilent Technologies). CRAE was developed in conditions of 50°C for 3 minutes, 50°C to 100°C at 20°C per minute, 100°C to 210°C at 10°C per minute, 210°C to 250°C at 8°C per minute, and 250°C for 4 minutes in helium carrier gas, with a flow rate of 1 mL per minute. The profile for organochloride pesticides standards was previously optimized and developed.
CRAE was subjected to high-performance liquid chromatography for fingerprinting analysis. The separation was performed with Waters model HPLC instrument, equipped with 626 pumps controlled by 600s interface module and a photodiode array detector 996; 10 µl of CRAE (0.5 mg/mL) was injected and eluted on an ACE 5 aqueous column (250 mm × 4.6 mm, id) with mobile phase of 0.05M potassium dihydrogen phosphate-HPLC graded acetonitrile (75:25). The flow rate was 1 mL per min. Berberine, jatrorrhizine, palmatine, and magnoflorine (0.05 mg/mL) were dissolved in methanol and injected as standard markers.
Cell Lines and Cell Culture
Two human HCC cell lines, Hep G2 and MHCC97L, were chosen for the following experiment. Hep G2 was purchased from ATCC, while MHCC97L was a gift by Dr Man Kwan in the Department of Surgery, The University of Hong Kong. Both cell lines were maintained in DMEM medium with 10% FBS and 1% penicillin/streptomycin. The cells were cultured in tissue culture flasks and maintained in humidified incubator at 37°C with 5% CO 2 .
Cell Viability Assay
Cell viability of Hep G2 and MHCC97L were determined by MTT assay based on the protocols described by Mosmann. 27 Both cells (7.0 × 10 4 cells/mL) were treated with CRAE in serial concentrations (512, 256, 128, 64, 32, 16, and 8 µg/mL) and incubated for 24 and 48 hours; 10 µL of 5 mg/mL of MTT (Sigma-Aldrich) solution was added to each well. After 4 hours of incubation, the supernatant was removed, and 100 µL of DMSO was added to dissolve the remaining formazan crystal. The absorbance was measured at a wavelength of 550 nm by Multiskan MS microplate reader (Labsystems, Finland).
VEGF Enzyme-Linked Immunosorbent Assay
Secretion of VEGF was measured by Human VEGF ELISA Kit (ExCell Biology, Shanghai) according to the manufacturer's protocol. Briefly, the culture supernatant was incubated with biotinylated antibody on anti-VEGF monoclonal antibody precoated 96-well plate for 1 hour. The wells were washed, and HRP-conjugated streptavidin was added to all wells for 30 minutes of incubation. The plate was washed, and TMB substrate solution was added to each well for another 30 minutes. Last, stop solution was added to each well before absorbance determination at 450 nm with Multiskan MS microplate reader. The experiment was conducted in triplicate.
Quantitative Real-Time Polymerase Chain Reaction
First, the total RNA was extracted with RNA isoplus reagent (Takara, Japan) according to the manufacturer's protocol. Each 0.5 µg of RNA sample was then reverse transcribed into cDNA (Reverse Transcription Kit, Takara). The quantitative real-time polymerase chain reaction was performed by SYBR Premix Ex Taq (Takara) with LightCycler 480 real-time polymerase chain reaction system (Roche, USA). The primer used was VEGF 5′-CCTCCGAAACCATGAACTTT-3′ (forward) and 5′-TTCTTTGGTCTGCATTCACATT-3′ (reverse). Relative quantification of mRNA levels was normalized with β-actin as the endogenous control.
Immunoblotting
The cell pellets were lysed with RIPA buffer supplemented with proteinase inhibitor (1% PMSF, 0.5% apotinin, and 0.5% leupitine) and phosphatase inhibitor (1mM Na3VO4 and 1mM NaF). Protein concentration was determined with BSA as standard, and 10 µg of protein sample was resolved by 10% sodium dodecyl-sulphate acrylamide gel and transferred to polyvinylidene difluoride membrane (Biorad, USA). The membrane was blocked with 5% BSA and probed with antibodies to α-tubulin, GADPH, eEF2, and peEF2 overnight. The membrane was then incubated with HRP-conjugated rabbit antibody before being visualized with ECL Advanced Kit (GE Healthcare, UK) by a chemiluminescence imaging system (Biorad).
Nascent Protein Synthesis
To label CRAE-treated Hep G2 and MHCC97L cells with Click-iT L-azidohomoalanine (AHA), the pretreated cells were cultured in methionine-free medium overnight; 30 µM of AHA was added to the cells, followed by 4 hours of incubation. The nascent proteins were extracted with Click-iT Protein Reaction Buffer Kit (Invitrogen, UK).
Xenograft Model
A xenograft tumor model was established in nude mice by subcutaneously injecting 1 × 10 6 MHCC97L cells/mL into the right flank of the mice. The tumors were allowed to grow for 7 days. CRAE treatment (50 mg/kg/2 days, intraperitoneal for 3 weeks) was initiated on 1 group of mice (n = 5), and another group (n = 5) was subjected with the same volume of PBS as control. The mice were sacrificed after 3 weeks with intraperitoneal injection of pentobarbital overdose (200 mg/kg); tumors were then removed and measured. The animal experimental protocol has obtained the approval from the Committee on the Use of Live Animals in Teaching and Research in The University of Hong Kong. After that, the tumors were subjected to immunohistochemistry staining to evaluate multivessel density and cellular proliferation of tumor cells with rat monoclonal antibody CD31 and Ki67 (AbCam).
Results
Quality Assessment of CRAE via GC-MS and HPLC
Comprehensive quality assessment was conducted to ensure the consistency and safety of the components in this herbal extract. To determine any presence of organochlorine pesticides in CRAE, it was subjected to GC-MS and analyzed under optimized chromatographic condition. The CRAE chemical profile was further compared to the previously obtained fingerprint profile of organochlorine pesticide standards, and there was no peak detected in CRAE (data available online, http://ict.sagepub.com/content/suppl). CRAE was subjected to HPLC analysis to confirm its quality before treatment. The HPLC fingerprint profile of CRAE was compared to the four external standard profiles based on its retention time and UV spectrum. The yield of four constituents was calculated and as follows: magnoflorine 2.2%, jatrorrhizine 1.68%, palmatine 4.4% and berberine 13.8% (Figure 1 ).
Expression of VEGF Was Blocked by CRAE at Nontoxic Doses
To evaluate the effect of CRAE on the expression of VEGF in HCC cells, we first evaluated the toxicity of the extract to HCC cell lines, Hep G2 and MHCC97L. The cytotoxicity of CRAE-treated MHCC97L and Hep G2 cells were determined after 24 and 48 hours of incubation. CRAE exerted 50% of cytotoxicity against MHCC97L at the dose of 500 and 150 µg/mL at 24 and 48 hours, respectively (Figure 2A ). As to Hep G2 cells, 50% of cell death was observed after treatment with 250 and 120 µg/mL of CRAE at 24 and 48 hours, respectively ( Figure 2B ). Based on the obtained results, the nontoxic doses of 75 and 150 µg/mL of CRAE were employed for further experiments. MHCC97L and HepG2 cells were then subjected to ELISA after exposure to CRAE for 24 hours. Results showed more than twofold secretory VEGF protein reduction in both cell lines compared to control ( Figure 2C ). These results indicated that extract of C rhizome could inhibit the VEGF expression, which is independent to its cytotoxicity.
CRAE-Regulated VEGF Expression Through Suppression of Nascent Protein Synthesis in HCC Cells
Previous studies 19, 20 has reported that berberine, the component in CRAE, could suppress the expression of VEGF in transcriptional regulatory manner. Therefore, we further examined if CRAE could have the same effect on VEGF transcripts. The mRNA level of VEGF in CRAE-treated HCC cells was determined by quantitative real-time polymerase chain reaction. Unexpectedly, no significant reduction of VEGF mRNA transcripts was observed in HCC cells after CRAE treatment. Instead, the amounts of VEGF mRNA increased threefold in CRAE-treated cells ( Figure 2D ). The result suggested that CRAE did not affect VEGF in transcriptional level but actively attenuated VEGF protein secretion. To further test the posttranscriptional effect of CRAE on VEGF, we carried out nascent protein synthesis on CRAEtreated HCC. The CRAE-treated cells were incubated with L-azidohomoalanine (AHA) in methionine-free medium for 4 hours. The AHA-incorporating nascent proteins were labeled with biotin-azide and further subjected to immunoblotting with streptavidin-HRP as secondary antibody. Pretreatment of CRAE on both cell lines blocked global cellular protein synthesis ( Figure 3A) . The result indicated the involvement of CRAE in attenuating nascent protein translation in HCC.
Inhibition of VEGF Nascent Protein Synthesis by CRAE Was Associated With eEF2 Inactivation
We observed CRAE-induced eEF2 phosphorylation in HCC cells, in which eEF2 was responsible for elongation process of cap-dependent translation. Western blot analysis showed phosphorylation of eEF2 in CRAE-treated MHCC97L and Hep G2 cells, suggesting the inactivation of eEF2 by CRAE ( Figure 3B ). This may indicate that blockade of VEGF nascent protein synthesis was associated with eEF2 inactivation in CRAE-treated HCC cells. To further confirm eEF2 phosphorylation by CRAE, HCC was incubated with or without eEF2k inhibitor, A-484954 (50 µM), together with CRAE for 24 hours. Incubation of HCC with A-484954 neutralized the expression of eEF2 ( Figure 4A ) and normalized the secretion of VEGF ( Figure 4B ), suggesting that CRAE attenuated eEF2-driven VEGF protein synthesis. Amounts of VEGF mRNA were increased in the presence of A-484954, and this correlated with the results obtained earlier, indicating that CRAE has no inhibitory effect on VEGF mRNA ( Figure 4C ). Taken together, the data showed that the inactivation of eEF2 activity by CRAE led to disruption in translation process.
Berberine Was the Major Active Component of CRAE in Inducing eEF2 Phosphorylation
To further elucidate the responsible constituent in CRAE that contributed to eEF2 phosphorylation, we incubated HCC cells with individual compounds for 24 hours: jatrorrhizine (2.52 µg/mL), berberine (20.7 µg/mL), and palmatine (6.6 µg/mL). Each compound's concentration was prepared on the basis of its proportion present in CRAE. Cell lysates were then subjected for eEF2 phosphorylation. Western blot analysis showed berberine and a mixture of 4 constituents were expressed at the same level in both cells, while berberine was the most active among them. However, a higher expression level of phosphorylated-eEF2 was observed in CRAE, postulating that other constituents present in CRAE may contribute to the activity ( Figure 5 ).
CRAE Reduced Tumor Size and Neovascularization in Xenograft HCC Model
To investigate the effect of CRAE on tumor growth in vivo, the MHCC97L xenograft mice were administrated with CRAE (50 mg/kg/2 days, intraperitoneal) for 3 weeks. After 3 weeks of CRAE administration, the body weight of mice remained unchanged (results not shown), indicating that CRAE has minimal toxicity to the animal at this dose. A significant reduction in tumor size was speculated in CRAE-treated mice in comparison to control ( Figure 6A ). The excised tumors were then measured. The tumor volumes of untreated and CRAE-treated mice were 1306.67 ± 100.7 mm 3 and 656.67 ± 485.2 mm 3 . Approximately twofold size reduction was observed in CRAE-treated mice ( Figure 6B ). Multivessel density and cellular proliferation was examined by hematoxylin and eosin staining on anti-CD31 and anti-Ki67 antibody. Histologic analysis against Ki-67 antibody showed a marked decrease in areas of proliferating cells in CRAE-treated mice compared to control. Presence of CD31-postive cells also apparently deceased in CRAE-treated mice ( Figure 6C ), indicating the reduced rate of new blood vessel formation. Compared to control group, CRAE-treated mice showed lower vascular density in tumor.
Discussion
This in vitro study has demonstrated that CRAE offsets VEGF secretion in HCC cells; however, it is not associated with downregulation of VEGF mRNA. Significant increase of VEGF mRNA after treatment may be the stabilization effect of hypoxia-induced factor-1 alpha transcriptional factor (HIF-1α) in tumor cells. 28 In our study, we surprisingly observed that the expression of VEGF could be inhibited by CRAE under normoxic condition, in which HIF-1α should not be present, indicating that CRAE-suppressed VEGF is mediated through HIF-1α-independent mechanism. This responsible effect was further justified where we found that CRAE has no inhibition on mRNA transcripts of VEGF, which may rule out the presence of transcriptional control in VEGF regulation by CRAE. We reported for the first time that CRAE could suppress the synthesis of nascent protein, which was translated on decoded ribosomes; the unfolded and extended chain of nascent protein was transported through translocon into endoplasmic reticulum for further folding. VEGF is a glycoprotein that synthesized inside ER, and ER stress could trigger VEGF upregulation transcriptionally and posttranslationally. 29 Our observation showed reduction of nascent protein synthesis after treatment with CRAE in dose-dependent manner. Consistent with these findings, CRAEtriggered eEF2 phosphorylation was followed by blockade of nascent protein synthesis, leading to the inhibitory effects of VEGF protein secretion. eEF2 is responsible for mediating ribosomal transfer in the elongation process of mRNA translation. eEF2 is inactivated by being phosphorylated at its Thr56 site, which leads to disruption in protein synthesis. 30 Overexpression and hyperactivity of eEF2 in cancer are associated with cancer cell progression and early tumor recurrence, 31, 32 and high level of protein synthesis is vital to maintain cancer cell metabolism. 33 Treatment with doxorubicin has been reported to phosphorylate eEF2 through interfering antiapoptotic protein and promote cancer cell death. 34 A previous report has postulated a novel energyconserved mechanism where translational arrest caused by eEF2 phosphorylation in an HIF-independent oxygen depletion condition. 35 Interestingly, in our study, we discovered eEF2 phosphorylation by CRAE in a dose-dependent manner, further justified through inhibition by A-484954. This suggests that CRAE may cause HCC to enter an energy-saving mechanism that renders posttranscriptional arrest and halts the production of other growth and angiogenic factors, such as VEGF.
Protein synthesis is an ATP-exhaustive process, and termination of mRNA translation turns out to be a tumor cell survival strategy. 36 Besides, elevation of VEGF protein in MHCC97L after A-484954 addition was observed, suggesting that posttranscriptional inhibitor may initiate cell compensation pathway to produce more VEGF protein. Our assumption was further supported by previous studies also reporting that VEGF inhibition may trigger cell survival adaptations to increase VEGF protein expression and receptor activity. 37, 38 The in vivo subcutaneous animal model showed a reduction of CD31-stained blood vessels and shrinkage of tumor size after treatment with CRAE. Data obtained have signified that inhibition of tumor angiogenesis was involved in the anticancer effect of CRAE in HCC. The regulatory scheme underlying the inhibitory effect of CRAE on VEGF expression in HCC cells is shown in Figure 7 .
Our previous study addressed the greater potential of C rhizome compared to treatment by berberine alone, and the effect was contributed by other protoberberine-type alkaloids present in C rhizome. 23 Consistent with previous study, we observed a higher level of eEF2 phosphorylation in CRAE, suggesting that other compounds may be responsible on the activity but that berberine was the most effective one. The current data indicate the additive effect of other constituents present in C rhizome.
Conclusion
In conclusion, we have elucidated the inhibition of VEGF protein synthesis by CRAE via an eEF2-driven pathway. CRAE blocked nascent protein synthesis and thereby inhibited VEGF protein formation. CRAE exhibits more potent inhibition on eEF2 activity than berberine alone, suggesting that the presence of other compounds in C rhizome may contribute an additive effect of eEF2 inactivation. This study postulates CRAE as a potential antiangiogenic substance for HCC.
